Eli Lilly and Company (LLY) - A Comprehensive Overview

Overview:
Eli Lilly and Company, a global pharmaceutical leader, is known for its extensive range of human pharmaceuticals. Founded in 1876 and headquartered in Indianapolis, LLY focuses on discovering, developing, and marketing pharmaceuticals worldwide.

Key Financials:

• As of December 31, 2022, LLY's total assets stood at $49.49 billion, with a significant portion in current assets ($18.03 billion) and non-current assets ($31.45 billion).
  
• Net sales/revenue saw a steady increase from $24.55 billion in 2018 to $28.54 billion in 2022.
  
• Gross profit also rose from $19.59 billion in 2018 to $23.31 billion in 2022.
  
• Net income displayed notable growth, especially in 2022, with $6.25 billion compared to $3.23 billion in 2018.
  
• LLY’s operating cash flow improved from $5.53 billion in 2018 to $7.08 billion in 2022.
  

Stock Performance:

• The stock price as of November 10, 2023, was $597.71, with a 52-week high of $629.97.
  
• Market Capitalization: $537.5 billion.
  
• The EPS growth was +14.7% from the prior TTM.
  

Market Position Against Competitors:

• LLY’s P/E ratio of 83.1 is significantly higher compared to industry peers like Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Merck & Co Inc (MRK), and Bristol-Myers Squibb Co (BMY), indicating a potentially higher growth expectation from the market.
  
• LLY's Price to Sales ratio is 18.2, showing a premium valuation compared to its competitors.
  
• Revenue growth at +1.5% is moderate compared to industry growth rates.
  

Investor Sentiment:

• The Equity Summary Score for LLY is neutral at 6.3, reflecting a balanced view among analysts.
  
• Analysts’ opinions show a mix of Neutral and Buy, with a significant positive outlook from firms like Jefferies, CSFB, and UBS.
  

Conclusion:
Eli Lilly and Company, with its strong financials, diverse product portfolio, and robust operational efficiency, remains a key player in the pharmaceutical industry. While it commands a premium valuation compared to its competitors, its consistent growth in key financial metrics, and innovative product pipeline, position it favorably for future growth. Investors and analysts maintain a cautiously optimistic view of the company's prospects in a competitive market.